Skip to Content
Merck
  • Differential monocyte responses to TLR ligands in children with autism spectrum disorders.

Differential monocyte responses to TLR ligands in children with autism spectrum disorders.

Brain, behavior, and immunity (2009-08-12)
Amanda M Enstrom, Charity E Onore, Judy A Van de Water, Paul Ashwood
ABSTRACT

Autism spectrum disorders (ASD) are characterized by impairment in social interactions, communication deficits, and restricted repetitive interests and behaviors. Recent evidence has suggested that impairments of innate immunity may play an important role in ASD. To test this hypothesis, we isolated peripheral blood monocytes from 17 children with ASD and 16 age-matched typically developing (TD) controls and stimulated these cell cultures in vitro with distinct toll-like receptors (TLR) ligands: TLR 2 (lipoteichoic acid; LTA), TLR 3 (poly I:C), TLR 4 (lipopolysaccharide; LPS), TLR 5 (flagellin), and TLR 9 (CpG-B). Supernatants were harvested from the cell cultures and pro-inflammatory cytokine responses for IL-1beta, IL-6, IL-8, TNFalpha, MCP-1, and GM-CSF were determined by multiplex Luminex analysis. After in vitro challenge with TLR ligands, differential cytokine responses were observed in monocyte cultures from children with ASD compared with TD control children. In particular, there was a marked increase in pro-inflammatory IL-1beta, IL-6, and TNFalpha responses following TLR 2, and IL-1beta response following TLR 4 stimulation in monocyte cultures from children with ASD (p<0.04). Conversely, following TLR 9 stimulation there was a decrease in IL-1beta, IL-6, GM-CSF, and TNFalpha responses in monocyte cell cultures from children with ASD compared with controls (p<0.05). These data indicate that, monocyte cultures from children with ASD are more responsive to signaling via select TLRs. As monocytes are key regulators of the immune response, dysfunction in the response of these cells could result in long-term immune alterations in children with ASD that may lead to the development of adverse neuroimmune interactions and could play a role in the pathophysiology observed in ASD.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, Ready Made solution, 1 mg/mL
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, FITC conjugate
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, Detoxified
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, purified by gel-filtration chromatography
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, purified by ion-exchange chromatography, TLR ligand tested
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, purified by trichloroacetic acid extraction
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, purified by phenol extraction
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Lipoteichoic acid from Staphylococcus aureus, bacterial cell wall polymer